Regenerating Damaged Myocardium: A Review of Stem-Cell Therapies for Heart Failure

Cardiovascular disease (CVD) is one of the contributing factors to more than one-third of human mortality and the leading cause of death worldwide. The death of cardiac myocyte is a fundamental pathological process in cardiac pathologies caused by various heart diseases, including myocardial infarct...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dihan Fan, Hanrong Wu, Kaichao Pan, Huashan Peng, Rongxue Wu
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	iPSCs ESC differentiation cardiovascular disease myocardial repair Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/5404da2f753c40d2bc7006a641273462
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5404da2f753c40d2bc7006a641273462
record_format	dspace
spelling	oai:doaj.org-article:5404da2f753c40d2bc7006a6412734622021-11-25T17:11:46ZRegenerating Damaged Myocardium: A Review of Stem-Cell Therapies for Heart Failure10.3390/cells101131252073-4409https://doaj.org/article/5404da2f753c40d2bc7006a6412734622021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/3125https://doaj.org/toc/2073-4409Cardiovascular disease (CVD) is one of the contributing factors to more than one-third of human mortality and the leading cause of death worldwide. The death of cardiac myocyte is a fundamental pathological process in cardiac pathologies caused by various heart diseases, including myocardial infarction. Thus, strategies for replacing fibrotic tissue in the infarcted region with functional myocardium have long been a goal of cardiovascular research. This review begins by briefly discussing a variety of somatic stem- and progenitor-cell populations that were frequently studied in early investigations of regenerative myocardial therapy and then focuses primarily on pluripotent stem cells (PSCs), especially induced-pluripotent stem cells (iPSCs), which have emerged as perhaps the most promising source of cardiomyocytes for both therapeutic applications and drug testing. We also describe attempts to generate cardiomyocytes directly from cardiac fibroblasts (i.e., transdifferentiation), which, if successful, may enable the pool of endogenous cardiac fibroblasts to be used as an in-situ source of cardiomyocytes for myocardial repair.Dihan FanHanrong WuKaichao PanHuashan PengRongxue WuMDPI AGarticleiPSCsESCdifferentiationcardiovascular diseasemyocardial repairBiology (General)QH301-705.5ENCells, Vol 10, Iss 3125, p 3125 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	iPSCs ESC differentiation cardiovascular disease myocardial repair Biology (General) QH301-705.5
spellingShingle	iPSCs ESC differentiation cardiovascular disease myocardial repair Biology (General) QH301-705.5 Dihan Fan Hanrong Wu Kaichao Pan Huashan Peng Rongxue Wu Regenerating Damaged Myocardium: A Review of Stem-Cell Therapies for Heart Failure
description	Cardiovascular disease (CVD) is one of the contributing factors to more than one-third of human mortality and the leading cause of death worldwide. The death of cardiac myocyte is a fundamental pathological process in cardiac pathologies caused by various heart diseases, including myocardial infarction. Thus, strategies for replacing fibrotic tissue in the infarcted region with functional myocardium have long been a goal of cardiovascular research. This review begins by briefly discussing a variety of somatic stem- and progenitor-cell populations that were frequently studied in early investigations of regenerative myocardial therapy and then focuses primarily on pluripotent stem cells (PSCs), especially induced-pluripotent stem cells (iPSCs), which have emerged as perhaps the most promising source of cardiomyocytes for both therapeutic applications and drug testing. We also describe attempts to generate cardiomyocytes directly from cardiac fibroblasts (i.e., transdifferentiation), which, if successful, may enable the pool of endogenous cardiac fibroblasts to be used as an in-situ source of cardiomyocytes for myocardial repair.
format	article
author	Dihan Fan Hanrong Wu Kaichao Pan Huashan Peng Rongxue Wu
author_facet	Dihan Fan Hanrong Wu Kaichao Pan Huashan Peng Rongxue Wu
author_sort	Dihan Fan
title	Regenerating Damaged Myocardium: A Review of Stem-Cell Therapies for Heart Failure
title_short	Regenerating Damaged Myocardium: A Review of Stem-Cell Therapies for Heart Failure
title_full	Regenerating Damaged Myocardium: A Review of Stem-Cell Therapies for Heart Failure
title_fullStr	Regenerating Damaged Myocardium: A Review of Stem-Cell Therapies for Heart Failure
title_full_unstemmed	Regenerating Damaged Myocardium: A Review of Stem-Cell Therapies for Heart Failure
title_sort	regenerating damaged myocardium: a review of stem-cell therapies for heart failure
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/5404da2f753c40d2bc7006a641273462
work_keys_str_mv	AT dihanfan regeneratingdamagedmyocardiumareviewofstemcelltherapiesforheartfailure AT hanrongwu regeneratingdamagedmyocardiumareviewofstemcelltherapiesforheartfailure AT kaichaopan regeneratingdamagedmyocardiumareviewofstemcelltherapiesforheartfailure AT huashanpeng regeneratingdamagedmyocardiumareviewofstemcelltherapiesforheartfailure AT rongxuewu regeneratingdamagedmyocardiumareviewofstemcelltherapiesforheartfailure
_version_	1718412649639706624

Regenerating Damaged Myocardium: A Review of Stem-Cell Therapies for Heart Failure

Ejemplares similares